Please click here for UK prescribing information and adverse event reporting information
This is a promotional material fully funded by Bayer and is intended for UK healthcare professionals only. EYLEA (aflibercept) 8 mg is indicated in adults for the treatment of nAMD, visual impairment due to DMO and visual impairment due to macular oedema secondary to RVO (branch, central and hemiretinal RVO). Please refer to the licensed EYLEA 8 mg SmPC for the full licensed posology and the full summary of the safety profile.
Global real-world evidence
Select a region to reveal findings
-
IRIS Registry and Vestrum
Health Retina DatabasenAMD
& DMO51,382
eyesPost-loading
phasePreviously
treated -
IRIS Registry and Vestrum
Health Retina DatabasenAMD6862
eyesPost-loading
phaseTreatment-
naïve
-
SPECTRUM
nAMD
& DMO572
eyes24
weeksTreatment-naïve &
previously treated -
Swiss study
nAMD
& DMO530
eyes12
monthsTreatment-naïve &
previously treated
Prescribing information
UK prescribing information and adverse event reporting information for EYLEA® (aflibercept) 40 mg/mL and 114.3 mg/mL solution for injection is available via the QR codes below. For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.
EYLEA® (aflibercept)
40 mg/mL
EYLEA® (aflibercept)
114.3 mg/mL
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/ or search MHRA Yellow Card in Google Play or Apple App Store.
Adverse events should also be reported to Bayer plc. If you want to report an adverse event or quality complaint, reports can be directed to Tel: 0118 206 3500 or Email: pvuk@bayer.com.Further information is available on the "contact" tab at www.bayer.co.uk.
Produced and funded by Bayer.